ClinicalTrials.gg
CompletedNCT02654002Updated Oct 12, 2020Results posted

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

A Phase 1 interventional study of Cilofexor and Placebo in Nonalcoholic Steatohepatitis (NASH), sponsored by Gilead Sciences. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-12.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.

Enrollment
12th of 16
120 · median 161
Started
2016
with 5 others
Phase 1
3 of 16
none open now
Registered
5th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 12th largest by enrollment, is one of 6 that started in 2016, is one of 3 in phase 1, and was the 5th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences as a file.
02

Study summary

This study will evaluate the safety and tolerability of escalating single- and multiple-oral doses of cilofexor, and characterize the single- and multiple-dose pharmacokinetics (PK) of cilofexor. The study will be conducted in 3 parts (Part A, Part B, and Part C). Participants will receive either cilofexor or cilofexor placebo.

Part A will proceed in 4 prespecified staggered cohorts. Within each cohort, the cumulative, blinded safety data will be evaluated for dose escalation from single-dose (Period 1) to multiple-dose (Period 2). Based on the available safety, pharmacokinetics, and/or pharmacodynamics (PD) data from cohorts in Part A and Part C (if applicable), total daily doses and frequency of dosing will be chosen for the cohorts in Part B. Parts B and C will consist of adaptive cohorts and may be initiated in parallel. Part B cohorts may be initiated in parallel with cohorts in Part A if the total dose under evaluation is at or below a dose already evaluated.

This study is partially blinded (no one is blinded on Day -1).

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy male and non-pregnant, non-lactating female volunteers
  • (BMI) 19 ≤ BMI ≤ 30 kg/m\^2
  • Normal 12-lead (ECG) or one with abnormalities that are considered clinically insignificant by the investigator
  • Normal renal function (estimated calculated using the equation ≥ 80 mL/min)
  • No significant medical history, and in good general health as determined by the investigator at screening evaluation performed no more than 28 days prior to the scheduled first dose.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Cohort 1: Cilofexor 10 mg

    Participants in fasted state will receive cilofexor 10 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.

    Drug: Cilofexor · Drug: Placebo

  • Experimental
    Cohort 2: Cilofexor 30 mg

    Participants in fasted state will receive cilofexor 30 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 30 mg or placebo once daily from Day 7 to Day 20.

    Drug: Cilofexor · Drug: Placebo

  • Experimental
    Cohort 3: Cilofexor 100 mg

    Participants in fasted state will receive cilofexor 100 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo once daily from Day 7 to Day 20.

    Drug: Cilofexor · Drug: Placebo

  • Experimental
    Cohort 4: Cilofexor 300 mg

    Participants in fasted state will receive cilofexor 300 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 300 mg or placebo once daily from Day 7 to Day 20.

    Drug: Cilofexor · Drug: Placebo

  • Experimental
    Cohort 5: Cilofexor 100 mg

    Participants in fed state will receive cilofexor 100 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo tablet, orally, once daily with food from Day 7 to Day 20.

    Drug: Cilofexor · Drug: Placebo

  • Experimental
    Cohort 6: Cilofexor 50 mg

    Participants in fed state will receive cilofexor 50 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 50 mg or placebo twice daily from Day 7 to Day 20.

    Drug: Cilofexor · Drug: Placebo

  • Experimental
    Cohort 7: Cilofexor 15 mg

    Participants in fed state will receive cilofexor 15 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 15 mg or placebo twice daily from Day 7 to Day 20.

    Drug: Cilofexor · Drug: Placebo

  • Experimental
    Cohort 8: Cilofexor 10 mg

    Participants in fed state will receive cilofexor 10 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.

    Drug: Cilofexor · Drug: Placebo

  • Experimental
    Cohort 9: Cilofexor

    Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.

    Drug: Cilofexor · Drug: Placebo

  • Experimental
    Cohort 10: Cilofexor

    Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.

    Drug: Cilofexor · Drug: Placebo

Interventions

  • Tablets administered orally

    Also known as: GS-9674

  • DrugPlacebo

    Tablets administered orally

06

What researchers measure

Primary outcomes

  1. Single-Dose Pharmacokinetic (PK) Parameter: AUClast of Cilofexor

    AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.

    Time frame: Day 1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose

  2. Single-Dose PK Parameter: AUCinf of Cilofexor

    AUCinf is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).

    Time frame: Day 1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose

  3. Single-Dose PK Parameter: Cmax of Cilofexor

    Cmax is defined as the maximum observed concentration of drug in plasma.

    Time frame: Day 1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose

  4. Multiple-Dose PK Parameter: AUCtau of Cilofexor

    AUCtau is the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval).

    Time frame: Day 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose

  5. Multiple-Dose PK Parameter: Cmax of Cilofexor

    Cmax is defined as the maximum observed concentration of drug in plasma.

    Time frame: Day 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose

  6. Multiple-Dose PK Parameter: Ctau of Cilofexor

    Ctau is defined as the observed drug concentration at the end of the dosing interval.

    Time frame: Day 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose

  7. Percentage of Participants With at Least One Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: First dose date up to last dose date (Maximum: 20 days) plus 30 days

  8. Percentage of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities

    Investigator determined the ECG findings were clinically significant.

    Time frame: First dose date up to last dose date (Maximum: 20 days) plus 30 days

  9. Percentage of Participants With Clinical Laboratory Abnormalities

    Treatment-emergent laboratory (Hematology, Chemistry, and Urinalysis) abnormalities were defined as values that increase at least one toxicity grade from baseline. Laboratory Abnormalities are graded by the investigator as Grade 1, 2, 3, or 4 according to the modified Gilead Sciences, Inc (GSI) Grading Scale. The most severe graded abnormality from all tests was counted for each participant. Data is only reported for those Grades reported in 1 or more participants.

    Time frame: First dose date up to last dose date (Maximum: 20 days) plus 30 days

Secondary outcomes

  1. Pharmacodynamic (PD) Parameter: Fibroblast Growth Factor 19 (FGF19) AUC2-12 Ratio

    AUC2-12 is defined as the AUC from time 2 to 12 hours. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the AUC2-12 Day 1 /AUC2-12 Day-1. The ratio reported for Day 20 is the AUC2-12 Day 20 /AUC2-12 Day-1.

    Time frame: Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose

  2. PD Parameter: FGF19 Cmax Ratio

    Cmax is defined as the maximum observed concentration of FGF19 in plasma. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the Cmax Day 1 /Cmax Day-1. The ratio reported for Day 20 is the Cmax Day 20 /Cmax Day-1.

    Time frame: Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose

  3. PD Parameter: 7alpha-hydroxy-4-cholesten-3-one (C4) AUC2-12 Ratio

    AUC2-12 is defined as the AUC from time 2 to 12 hours. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the AUC2-12 Day 1 /AUC2-12 Day-1. The ratio reported for Day 20 is the AUC2-12 Day 20 /AUC2-12 Day-1.

    Time frame: Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose

  4. PD Parameter: C4 Cmin Ratio

    Cmin is defined as the minimum observed concentration of C4 in plasma. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the Cmin Day 1 /Cmin Day-1. The ratio reported for Day 20 is the Cmin Day 20 /Cmin Day-1.

    Time frame: Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose

07

Results

Posted Oct 12, 2020

Participant flow

Participants were enrolled at one study site in the United States. The first participant was screened on 20 January 2016. The last study visit occurred on 14 July 2016.

Participant flow — Overall Study
MilestoneCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll Placebo
Started121212121212121224
Completed121212121211111124
Not completed000001110
Withdrew: Adverse event000000100
Withdrew: Withdrew consent000001010

Outcome measures

PrimarySingle-Dose Pharmacokinetic (PK) Parameter: AUClast of Cilofexor

AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.

Time frame:
Day 1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Mean · hours*nanogram/millilitre (h*ng/mL)
Single-Dose Pharmacokinetic (PK) Parameter: AUClast of Cilofexor
hours*nanogram/millilitre (h*ng/mL)Cohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mg
Single-Dose Pharmacokinetic (PK) Parameter: AUClast of Cilofexor1236.0 ± 384.652450.6 ± 921.707712.1 ± 7270.7612458.8 ± 4223.124979.5 ± 2039.073091.4 ± 752.661301.9 ± 388.51905.9 ± 210.24
PrimarySingle-Dose PK Parameter: AUCinf of Cilofexor

AUCinf is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).

Time frame:
Day 1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Mean · h*ng/mL
Single-Dose PK Parameter: AUCinf of Cilofexor
h*ng/mLCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mg
Single-Dose PK Parameter: AUCinf of Cilofexor1255.9 ± 382.372473.4 ± 920.857743.7 ± 7273.5012495.7 ± 4230.005016.7 ± 2022.943559.2 ± 1092.731409.3 ± 428.33924.0 ± 216.60
PrimarySingle-Dose PK Parameter: Cmax of Cilofexor

Cmax is defined as the maximum observed concentration of drug in plasma.

Time frame:
Day 1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Mean · ng/mL
Single-Dose PK Parameter: Cmax of Cilofexor
ng/mLCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mg
Single-Dose PK Parameter: Cmax of Cilofexor304.2 ± 126.66580.2 ± 283.792592.3 ± 3059.313055.5 ± 2022.27927.6 ± 540.94665.9 ± 152.30340.2 ± 124.44209.8 ± 63.24
PrimaryMultiple-Dose PK Parameter: AUCtau of Cilofexor

AUCtau is the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval).

Time frame:
Day 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Mean · h*ng/mL
Multiple-Dose PK Parameter: AUCtau of Cilofexor
h*ng/mLCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mg
Multiple-Dose PK Parameter: AUCtau of Cilofexor1284.9 ± 460.352891.0 ± 680.106719.4 ± 3980.908486.0 ± 4139.864182.7 ± 1956.033698.3 ± 837.911293.5 ± 250.95848.2 ± 213.82
PrimaryMultiple-Dose PK Parameter: Cmax of Cilofexor

Cmax is defined as the maximum observed concentration of drug in plasma.

Time frame:
Day 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Mean · ng/mL
Multiple-Dose PK Parameter: Cmax of Cilofexor
ng/mLCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mg
Multiple-Dose PK Parameter: Cmax of Cilofexor322.2 ± 136.70717.5 ± 235.502231.2 ± 1693.782327.9 ± 1897.48818.7 ± 437.28697.8 ± 145.60290.4 ± 78.71187.0 ± 57.10
PrimaryMultiple-Dose PK Parameter: Ctau of Cilofexor

Ctau is defined as the observed drug concentration at the end of the dosing interval.

Time frame:
Day 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Mean · ng/mL
Multiple-Dose PK Parameter: Ctau of Cilofexor
ng/mLCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mg
Multiple-Dose PK Parameter: Ctau of Cilofexor2.7 ± 1.537.9 ± 3.9736.3 ± 15.4470.1 ± 39.4622.6 ± 8.44107.6 ± 84.5828.4 ± 14.133.0 ± 1.54
PrimaryPercentage of Participants With at Least One Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
First dose date up to last dose date (Maximum: 20 days) plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event (AE)
percentage of participantsCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll Placebo
Percentage of Participants With at Least One Adverse Event (AE)33.325.033.325.041.727.375.018.229.2
PrimaryPercentage of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities

Investigator determined the ECG findings were clinically significant.

Time frame:
First dose date up to last dose date (Maximum: 20 days) plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities
percentage of participantsCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll Placebo
Percentage of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities000000000
PrimaryPercentage of Participants With Clinical Laboratory Abnormalities

Treatment-emergent laboratory (Hematology, Chemistry, and Urinalysis) abnormalities were defined as values that increase at least one toxicity grade from baseline. Laboratory Abnormalities are graded by the investigator as Grade 1, 2, 3, or 4 according to the modified Gilead Sciences, Inc (GSI) Grading Scale. The most severe graded abnormality from all tests was counted for each participant. Data is only reported for those Grades reported in 1 or more participants.

Time frame:
First dose date up to last dose date (Maximum: 20 days) plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Laboratory Abnormalities
percentage of participantsCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll Placebo
Activated Partial Thromboplastin Time: Grade 10.08.316.70.00.00.00.00.00.0
Hemoglobin-Hypo: Grade 116.725.016.78.316.718.225.027.329.2
Hemoglobin-Hypo: Grade 20.00.08.38.38.30.016.79.18.3
Hemoglobin-Hypo: Grade 30.00.00.08.30.00.00.00.00.0
International Normalized Ratio: Grade 20.00.00.00.08.30.00.00.00.0
Lymphocytes: Grade 10.08.30.00.00.00.00.00.00.0
Platelets: Grade 20.08.30.00.00.00.00.00.00.0
Alanine Aminotransferase: Grade 10.00.00.08.30.00.00.09.14.2
Alanine Aminotransferase: Grade 20.016.70.00.08.39.10.00.04.2
Alanine Aminotransferase: Grade 30.00.00.00.00.00.08.30.00.0
Aspartate Aminotransferase: Grade 10.00.00.00.08.39.10.00.04.2
Aspartate Aminotransferase: Grade 20.08.30.00.00.00.08.30.00.0
Aspartate Aminotransferase: Grade 30.08.30.00.00.00.00.00.00.0
Aspartate Aminotransferase: Grade 40.00.00.00.00.00.00.00.04.2
Albumin Corrected Calcium-Hyper: Grade 10.00.00.08.38.39.18.30.04.2
Gamma-Glutamyltransferase: Grade 10.00.08.30.00.00.00.00.04.2
Gamma-Glutamyltransferase: Grade 20.00.00.00.00.00.08.30.00.0
Low-Density Lipoprotein: Grade 18.30.08.38.325.027.325.018.212.5
Low-Density Lipoprotein: Grade 28.38.38.38.316.70.08.30.04.2
Phosphate-Hypo: Grade 10.08.30.08.38.30.08.39.14.2
Phosphate-Hypo: Grade 20.00.00.00.00.00.00.00.04.2
Serum Amylase: Grade 10.08.30.00.00.00.00.00.00.0
Serum Amylase: Grade 20.00.00.00.00.00.00.09.14.2
Serum Glucose,Fasting-Hyper: Grade 10.08.30.00.00.00.00.00.00.0
Serum Glucose,Fasting-Hyper:Grade 20.00.00.00.00.00.00.09.10.0
Serum Glucose,Non-Fasting-Hyper:Grade 10.00.00.00.058.30.018.20.04.2
Serum Glucose,Non-Fasting-Hyper:Grade 20.00.00.00.00.00.00.09.10.0
Serum Glucose,Non-Fasting-Hypo:Grade 10.00.00.00.08.30.00.00.04.2
Serum Potassium-Hypo:Grade 10.08.30.00.00.00.00.027.30.0
Serum Sodium-Hyper:Grade 10.00.00.00.00.00.00.09.10.0
Serum Sodium-Hypo:Grade 18.325.08.30.00.018.250.09.14.2
Total Bilirubin-Hyper:Grade 10.00.00.08.30.00.00.09.14.2
Total Cholesterol-Hyper:Grade 116.70.016.716.725.036.425.09.112.5
Total Cholesterol-Hyper:Grade 28.30.08.30.016.70.08.39.14.2
Uric Acid-Hyper:Grade 10.00.08.30.00.00.00.00.00.0
Uric Acid-Hypo:Grade 18.316.70.08.30.00.00.00.00.0
Occult Blood: Grade 10.00.08.30.08.30.00.09.18.3
Occult Blood: Grade 216.78.30.08.30.00.00.09.112.5
Occult Blood: Grade 325.08.38.316.78.318.216.718.28.3
Urine Glucose: Grade 10.00.00.00.00.00.00.09.10.0
Urine Protein: Grade 10.08.30.00.00.00.00.00.04.2
SecondaryPharmacodynamic (PD) Parameter: Fibroblast Growth Factor 19 (FGF19) AUC2-12 Ratio

AUC2-12 is defined as the AUC from time 2 to 12 hours. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the AUC2-12 Day 1 /AUC2-12 Day-1. The ratio reported for Day 20 is the AUC2-12 Day 20 /AUC2-12 Day-1.

Time frame:
Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ratio
Pharmacodynamic (PD) Parameter: Fibroblast Growth Factor 19 (FGF19) AUC2-12 Ratio
ratioCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgAll Fasted PlaceboCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll Fed Placebo
Day 1/Day -12.040 (1.571 to 2.650)1.958 (1.478 to 2.594)2.037 (1.699 to 2.442)2.314 (1.958 to 2.735)0.981 (0.777 to 1.240)2.406 (2.196 to 2.637)2.629 (2.369 to 2.917)1.743 (1.463 to 2.076)1.372 (1.132 to 1.663)0.916 (0.799 to 1.050)
Day 20/Day -12.270 (1.500 to 3.435)2.261 (1.782 to 2.868)2.054 (1.727 to 2.442)2.179 (1.632 to 2.911)1.249 (0.929 to 1.681)1.795 (1.544 to 2.086)2.119 (1.728 to 2.598)1.650 (1.301 to 2.093)1.509 (1.325 to 1.719)0.963 (0.762 to 1.216)
SecondaryPD Parameter: FGF19 Cmax Ratio

Cmax is defined as the maximum observed concentration of FGF19 in plasma. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the Cmax Day 1 /Cmax Day-1. The ratio reported for Day 20 is the Cmax Day 20 /Cmax Day-1.

Time frame:
Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ratio
PD Parameter: FGF19 Cmax Ratio
ratioCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgAll Fasted PlaceboCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll Fed Placebo
Day 1/Day -12.217 (1.667 to 2.949)2.084 (1.468 to 2.957)2.259 (1.742 to 2.930)2.679 (2.113 to 3.398)0.982 (0.759 to 1.272)2.793 (2.264 to 3.446)2.973 (2.578 to 3.428)1.961 (1.588 to 2.422)1.689 (1.354 to 2.106)0.929 (0.810 to 1.065)
Day 20/Day -12.157 (1.345 to 3.460)2.393 (1.770 to 3.235)2.325 (1.804 to 2.996)3.084 (2.194 to 4.334)1.210 (0.910 to 1.608)2.241 (1.850 to 2.713)2.455 (1.964 to 3.069)1.768 (1.270 to 2.462)1.878 (1.527 to 2.310)0.874 (0.680 to 1.123)
SecondaryPD Parameter: 7alpha-hydroxy-4-cholesten-3-one (C4) AUC2-12 Ratio

AUC2-12 is defined as the AUC from time 2 to 12 hours. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the AUC2-12 Day 1 /AUC2-12 Day-1. The ratio reported for Day 20 is the AUC2-12 Day 20 /AUC2-12 Day-1.

Time frame:
Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ratio
PD Parameter: 7alpha-hydroxy-4-cholesten-3-one (C4) AUC2-12 Ratio
ratioCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgAll Fasted PlaceboCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll Fed Placebo
Day 1/Day -10.681 (0.431 to 1.077)0.640 (0.516 to 0.794)0.427 (0.340 to 0.537)0.347 (0.278 to 0.433)1.147 (0.921 to 1.429)0.837 (0.629 to 1.114)0.653 (0.581 to 0.735)0.863 (0.747 to 0.997)1.108 (0.828 to 1.483)1.057 (0.893 to 1.252)
Day 20/Day -10.661 (0.456 to 0.959)0.382 (0.277 to 0.525)0.495 (0.348 to 0.704)0.325 (0.223 to 0.474)1.213 (0.828 to 1.777)0.621 (0.414 to 0.933)0.173 (0.109 to 0.275)0.624 (0.472 to 0.825)0.974 (0.677 to 1.402)0.843 (0.681 to 1.043)
SecondaryPD Parameter: C4 Cmin Ratio

Cmin is defined as the minimum observed concentration of C4 in plasma. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the Cmin Day 1 /Cmin Day-1. The ratio reported for Day 20 is the Cmin Day 20 /Cmin Day-1.

Time frame:
Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ratio
PD Parameter: C4 Cmin Ratio
ratioCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgAll Fasted PlaceboCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll Fed Placebo
Day 1/Day -10.715 (0.531 to 0.964)0.759 (0.597 to 0.964)0.663 (0.542 to 0.810)0.467 (0.370 to 0.589)1.201 (0.941 to 1.532)0.613 (0.497 to 0.756)0.348 (0.260 to 0.467)0.737 (0.590 to 0.921)0.961 (0.787 to 1.173)1.162 (0.981 to 1.377)
Day 20/Day -10.822 (0.580 to 1.163)0.456 (0.303 to 0.687)0.624 (0.458 to 0.850)0.432 (0.277 to 0.675)1.262 (0.901 to 1.767)0.440 (0.264 to 0.733)0.116 (0.071 to 0.192)0.508 (0.334 to 0.773)0.862 (0.666 to 1.115)0.983 (0.718 to 1.346)

Adverse events

Collected over First dose date up to last dose date (Maximum: 20 days) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Cilofexor 10 mg0/12 (0%)0/12 (0%)4/12 (33.3%)
Cohort 2: Cilofexor 30 mg0/12 (0%)0/12 (0%)3/12 (25%)
Cohort 3: Cilofexor 100 mg0/12 (0%)0/12 (0%)4/12 (33.3%)
Cohort 4: Cilofexor 300 mg0/12 (0%)0/12 (0%)3/12 (25%)
Cohort 5: Cilofexor 100 mg0/12 (0%)0/12 (0%)5/12 (41.7%)
Cohort 6: Cilofexor 50 mg0/11 (0%)0/11 (0%)3/11 (27.3%)
Cohort 7: Cilofexor 15 mg0/12 (0%)0/12 (0%)9/12 (75%)
Cohort 8: Cilofexor 10 mg0/11 (0%)0/11 (0%)2/11 (18.2%)
All Placebo0/24 (0%)0/24 (0%)6/24 (25%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventCohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll Placebo
HeadacheNervous system disorders0/120/120/121/122/121/115/120/113/24
AnaemiaBlood and lymphatic system disorders0/120/120/120/122/120/110/120/110/24
DiarrhoeaGastrointestinal disorders0/120/120/120/122/120/111/120/110/24
Diabetes mellitusMetabolism and nutrition disorders0/120/120/120/120/120/110/121/110/24
Back painMusculoskeletal and connective tissue disorders1/121/121/120/121/121/110/120/110/24
SciaticaNervous system disorders0/120/120/120/120/120/110/121/110/24
EcchymosisSkin and subcutaneous tissue disorders0/120/120/120/120/121/110/120/110/24
Iron deficiency anaemiaBlood and lymphatic system disorders0/120/121/121/120/120/111/120/111/24
Ocular discomfortEye disorders1/120/120/120/120/120/110/120/110/24
Abdominal painGastrointestinal disorders0/120/120/120/121/120/111/120/110/24

Baseline characteristics

The Safety Analysis Set included all randomized participants who took at least 1 dose of study drug. Participants were grouped according to the treatment they actually received.

Age, Continuous
Age, Continuous(years)Cohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll PlaceboTotal
Mean34 ± 6.535 ± 8.937 ± 6.132 ± 8.740 ± 4.633 ± 7.435 ± 6.035 ± 7.136 ± 6.735 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll PlaceboTotal
Female645456781459
Male687875531059
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll PlaceboTotal
Hispanic or Latino111211121211121124116
Not Hispanic or Latino1010000002
Unknown or Not Reported0000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll PlaceboTotal
Race — Black11232212216
Race — White111110910911922102
Region of Enrollment
Region of Enrollment(participants)Cohort 1: Cilofexor 10 mgCohort 2: Cilofexor 30 mgCohort 3: Cilofexor 100 mgCohort 4: Cilofexor 300 mgCohort 5: Cilofexor 100 mgCohort 6: Cilofexor 50 mgCohort 7: Cilofexor 15 mgCohort 8: Cilofexor 10 mgAll PlaceboTotal
United States121212121211121124118
08

Study locations

1 site
  • SeaView Research, Inc
    Miami, Florida, United States
09

References and documents

Publications

  • Djedjos CS, Kirby BJ, Billin A, Gosink J, Song Q, Srihari R, et al. Pharmacodynamic Effects of the Oral, Non-Steroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers. The 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting (AASLD); 2016 November 11-15; Boston MA United States.
  • Kirby BJ, Djedjos CS, Birkeback J, Song Q, Grycz K, Weston J, et al. Evaluation of the Safety and Pharmacokinetics of the Oral, Nonsteroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers. The 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting (AASLD); 2016 November 11-15; Boston MA United States.
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jul 2016, 5 months.

Results were first posted in Oct 2020, 4 years 2 months after primary completion.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2016
First posted
Jan 13, 2016
StartActual
Jan 20, 2016
Primary completionActual
Jul 14, 2016
CompletionActual
Jul 14, 2016
Results first posted
Oct 12, 2020
Last update
Oct 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02654002
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 13, 2016
Start date
Jan 20, 2016
Primary completion
Jul 14, 2016
Completion
Jul 14, 2016
Results posted
Oct 12, 2020
Last update
Oct 12, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilofexor

Start the discussion